Levodopa inhalation - Acorda Therapeutics

Drug Profile

Levodopa inhalation - Acorda Therapeutics

Alternative Names: CVT-301; INBRIJA; Inhaled L-dopa - Civitas Therapeutics

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Civitas Therapeutics
  • Developer Acorda Therapeutics
  • Class Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Parkinson's disease
  • Phase I Asthma; Smoking withdrawal

Most Recent Events

  • 07 Dec 2017 Acorda Therapeutics resubmits NDA to the US FDA for Parkinson's disease
  • 31 Oct 2017 Acorda Therapeutics announces intention to re-submit NDA for Parkinson's disease in fourth quarter of 2017
  • 31 Oct 2017 Acorda Therapeutics announces its intention to submit a MAA in Europe for Parkinson's disease in first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top